

Daria R Bulanova

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/4807626/publications.pdf>

Version: 2024-02-01

10
papers

194
citations

1163117

8
h-index

1372567

10
g-index

10
all docs

10
docs citations

10
times ranked

426
citing authors

#	ARTICLE	IF	CITATIONS
1	Antiviral Properties of Chemical Inhibitors of Cellular Anti-Apoptotic Bcl-2 Proteins. <i>Viruses</i> , 2017, 9, 271.	3.3	39
2	Adaptive RSK&EphA2&GPRC5A signaling switch triggers chemotherapy resistance in ovarian cancer. <i>EMBO Molecular Medicine</i> , 2020, 12, e11177.	6.9	39
3	BRCA1-deficient breast cancer cell lines are resistant to MEK inhibitors and show distinct sensitivities to 6-thioguanine. <i>Scientific Reports</i> , 2016, 6, 28217.	3.3	23
4	Loss of DIAPH1 causes SCBMS, combined immunodeficiency, and mitochondrial dysfunction. <i>Journal of Allergy and Clinical Immunology</i> , 2021, 148, 599-611.	2.9	23
5	Pan-RAF inhibition induces apoptosis in acute myeloid leukemia cells and synergizes with BCL2 inhibition. <i>Leukemia</i> , 2020, 34, 3186-3196.	7.2	22
6	Improved detection of differentially represented DNA barcodes for high&throughput clonal phenomics. <i>Molecular Systems Biology</i> , 2020, 16, e9195.	7.2	15
7	Orphan G protein-coupled receptor GPRC5A modulates integrin $\alpha 1$ -mediated epithelial cell adhesion. <i>Cell Adhesion and Migration</i> , 2017, 11, 434-446.	2.7	13
8	Chemical, Physical and Biological Triggers of Evolutionary Conserved Bcl-xL-Mediated Apoptosis. <i>Cancers</i> , 2020, 12, 1694.	3.7	13
9	Selective drug combination vulnerabilities in STAT3- and TP53-mutant malignant NK cells. <i>Blood Advances</i> , 2021, 5, 1862-1875.	5.2	5
10	Response to: The <i>GPRC5A</i> frameshift variant c.183del is not associated with increased breast cancer risk in <i>BRCA1</i> mutation carriers. <i>International Journal of Cancer</i> , 2019, 144, 1758-1760.	5.1	2